Table 11.
Dasatinib pediatric leukemia trials in http://www.clinicaltrials.gov
| Number | Abbreviated title | NCT number | Age | Sponsor |
|---|---|---|---|---|
| 1 | Dasatinib in R/R leukemia | 00306202 | 12 months to 20 years | BMS |
| 2 | Dasatinib in CML | 00777036 | ≤18 years | BMS |
| 3 | Dasatinib and CCT in ALL | 00720109 | 2–30 years | NCI |
| 4 | Dasatinib in malignancy not responding to imatinib | 00316953 | 1–21 years | NCI |
| 5 | Newly-diagnosed ALL | 00549848 | ≤18 years | St Jude CRH |
| 6 | Ph+ ALL | 01460160 | 1–17 years | BMS |
| 7 | Nilotinib in Ph+ CML | 01844765 | 1–18 years | Novartis |
| 8 | PK nilotinib in Ph+ CML or ALL | 01077544 | 1–18 years | Novartis |
| 9 | Dasatinib in imatinib-resistant or intolerant CML | 00866736 | ≥15 years | Kanto CML Study Group |
| 10 | Ruxolitinib or dasatinib with CT in Ph-like ALL | 02420717 | ≥10 years | MD Anderson Cancer Center |
| 11 | Dasatinib in CML in Japan | 01464411 | ≥20 months | Kanto CML Study Group |
| 12 | Dasatinib in CML | 00254423 | ≥16 years | MD Anderson Cancer Center |
| 13 | Assessment of Gh–Igf-1 axis in CML in remission | 01901666 | ? | PIMER, India |
| 14 | CT + irradiation + PBSCT in ALL or CML responding to TKI | 00036738 | ≤70 years | Hutchinson CRC |
| 15 | Dasatinib stop trial in CML | 01627132 | ≥15 years | Shimousa HSG |
| 16 | Dasatinib + CT in adults with Ph+ ALL | 01004497 | 15–65 years | Catholic University of Korea |
| 17 | Dasatinib in CML or ALL | 00103701 | ≥14 years | BMS |
| 18 | Dasatinib in CML | 01887561 | ≥15 years | Kanto CML Study Group |
| 19 | Korean post-marketing surveillance of dasatinib | 01464047 | ? | BMS |
| 20 | IL-11 and dasatinib in CML | 00493181 | ? | MD Anderson Cancer Center |
| 21 | Pegasys in CML | 01392170 | ≥16 years | MD Anderson Cancer Center |
| 22 | Azacytidine in MRD CML | 01460498 | ≥16 years | MD Anderson Cancer Center |
| 23 | Treatment modification in CML | 01762969 | ≥16 years | Rabin Medical Center |
Notes: The listed studies were the result of the search terms “dasatinib children leukemia”, which resulted in 26 hits. Study NCT00364286 had only recruited adults; studies NCT00563290 and NCT00070499 recruited only patients ≥18 years old. These studies were not included in the table.
Abbreviations: NCT, National Clinical Trial; R/R, relapsed or refractory; BMS, Bristol Meyer Squibb; CML, chronic myeloid leukemia; CCT, combination chemotherapy; ALL, acute lymphoblastic leukemia; NCI, National Cancer Institute; CRH, Children Research Hospital; Ph+, Philadelphia chromosome-positive; PK, pharmacokinetics; CT, chemotherapy; PIMER, Postgraduate Institute of Medical Education and Research; PBSCT, peripheral blood stem cell transplantation; TKI, tyrosine kinase inhibitor; CRC, Cancer Research Center; HSG, Hematology Study Group; IL-11, interleukin 11; MRD, minimal residual disease.